We are thrilled to announce our multi-regional licensing agreement with Energenesis Biomedical for the innovative treatment ENERGI-F703DFU, currently in Phase III trials for diabetic foot ulcers (DFU).
This partnership marks a significant step in our mission to enhance diabetic care in emerging markets, including Portugal and parts of the Middle East, with potential expansions to Africa and Latin America.
Pharma Bavaria is committed to making a difference in the lives of those living with diabetes. Stay tuned for updates as we work to bring this groundbreaking treatment to market!
Full Press Release (PDF)
